Will use Oracle Health Clinical AI Agent to help doctors spend more time with patients Plans to replace disparate legacy systems with Oracle Health Foundation EHR to drive efficiency, improve care coordination Community Memorial Hospital (CMH) will replace its legacy health record systems with Oracle Health solutions to support innovation, optimize growth, and increase operational […]
Kaffea-X today announced the launch of its digital marketplace for specialty green coffee, designed to address long-standing challenges in global coffee trading related to price opacity, fragmented attributes description standards, and counterparty risk. The platform introduces a standardized product identification system, alongside escrow-backed transaction settlement, providing market participants with transparent price discovery and institutional-grade payment
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Varonis Systems, Inc. (NASDAQ: VRNS) common stock between February 4, 2025 and October 28, 2025, both dates inclusive (the “Class Period”), have until March 9, 2026 to seek appointment as lead plaintiff of the Varonis class action lawsuit. Captioned Molchanov v. Varonis Systems,
MNP Consumer Debt Index: Canadians Brace for Challenging 2026 Majority of Canadians Anticipate Higher Living Costs (71%), Rising Housing Pressure (59%), Worsening Economy (59%), Interest Rate and Inflation Strain (54%), and Job Market Weakness (52%) This Year GlobeNewswire January 12, 2026 CALGARY, Alberta, Jan. 12, 2026 (GLOBE NEWSWIRE) — Canadians are heading into the new
OSR Holdings, Inc. (NASDAQ: OSRH) today announced that its Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG confirming BCM Europe’s interest in entering a global exclusive licensing transaction for VXM01, Vaximm’s lead immunotherapy candidate. Under the terms of the binding term sheet, BCM Europe intends to establish and
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, and Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical collaboration to conduct a Phase 1 trial in China, planned to begin in 2026. The trial will
Veteran advisor focused on empathetic service, transparent guidance, and lifelong client relationships selects Cetera to support her growth plans Cetera welcomes financial advisor Kim Ramchandani and her deeply personal, relationship-driven approach to financial planning that emphasizes education, transparency and long-term client support. She now is affiliating with Cetera after nearly 20 years at LPL, where
(NASDAQ:SLDB), CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the first participant has been dosed in FALCON, the Company's Phase 1b, first-in-human clinical trial evaluating SGT-212, its investigational gene therapy
(NASDAQ:CARL), Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024 CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced preliminary and
(NASDAQ:BLLN), MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the full